News about 'r&d'

From Guardian (UK) (March 3, 2011) AstraZeneca has joined a consortium to fight tuberculosis around the world with French rival Sanofi-aventis, the University of Cambridge and other research organisations. The More Medicines for Tuberculosis (MM4TB) consortium intends to develop new drugs for...

2010 G-Finder Report The third annual G-Finder report, Neglected Disease Research and Development, was released on February 16, 2011. The report, compiled by the Policy Cures staff using information self-reported by granting and recipient institutions, provides the latest information on the funding...

Elkington PT, D’Armiento JM, Friedland JS. Tuberculosis immunopathology: the neglected role of extracellular matrix destruction. Sci Transl Med. 2011 Feb 23;3(71):71ps6. In today’s article, Elkington, et al., would like to change how researchers view and define immunopathology in tuberculosis. The...

Summary: Dr. Philip Bourne is a professor at the University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences and Editor in Chief of PL0S Computational Biology . The WGND had the opportunity to talk with Dr. Bourne on a recent article published in PLoS Computational...

[wpaudio url=”/blog/media/podcasts/Anne_Lenaerts_Interview_edited-norm.mp3″ text=”Anne Lenaerts Interview” dl=”0″] Summary: Dr. Anne Lenaerts is an associate professor at Colorado State University”s College of Veterinary Medicine and Biomedical Sciences in the Department of Microbiology, Immunology...

The Bill & Melinda Gates Foundation is now accepting letters of inquiry for the new grant program Biomarkers for the Diagnosis of Tuberculosis. This grant program is part of the Grand Challenges in Global Health initiative. With up to $12 million of funding, the program seeks to validate...

Chemical Structure of Pyrazinamide Ahmad Z, Fraig MM, Bisson GP, Nuermberger EL, Grosset JH, Karakousis PC. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis. Antimicrob Agents Chemother. 2011 Jan 31. [Epub ahead of print] First discovered as...

5-Jul-2011 - 8-Jul-2011 | Montreal, Quebec, Canada Context High quality diagnostic studies are critical to evaluate new tools, to develop evidence-based policies on TB diagnostics. There is evidence that TB diagnostic trials are poorly conducted and poorly reported. Lack of methodologic rigour in...

Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, Schoolnik GK, Cassidy JP, Billeskov R, Andersen P. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med. 2011 Jan 23. [Epub ahead of print] Claus Aagaard, et al., presented a series of...

Saunders NJ, Urmi HT, Thomson ML, Doig C, Laurenson IF, Blaxter ML. Stepwise mutation to multiple drug resistance in Mycobacterium tuberculosis in an otherwise stable genetic backgrounddoes not support models of high mutation in the host and emphasizes the need for maintained effective...

Ahmad Z, Peloquin CA, Singh RP, Derendorf H, Tyagi S, Ginsberg A, Grosset JH, Nuermberger EL. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother. 2011 Jan;55(1):239-45. Epub 2010 Oct 11.PMID: 20937781 [PubMed – in process] Researchers testing the...

ELIMINATING TB BY 2050: AN ACCELERATED GLOBAL RESEARCH STRATEGY PLEASE PARTICIPATE TO HELP TB RESEARCH MOVING FORWARD As a member of the large TB community, you might well be aware of the fact that research is essential for speeding up progress towards Tuberculosis (TB) elimination by 2050. We need...

Raghuvanshi S, Sharma P, Singh S, Van Kaer L, Das G. Mycobacterium tuberculosis evades host immunity by recruiting mesenchymal stem cells. Proc Natl Acad Sci U S A. 2010 Dec 6. [Epub ahead of print] On the early drug discovery front, this study may provide researchers additional areas to target for...

New TB/HIV Working Group Report: Priority Research Questions for TB&HIV in HIV-Prevalent and Resource-Limited Settings TB-HIV Report Nov 2010 In November 2008, the Global TB/HIV Working Group of the Stop TB Partnership , in collaboration with the WHO Stop TB and HIV/AIDS departments and the...

2010 Annual Meeting Following the guest speakers ( click here to view that recap ), several representatives from companies conducting clinical trials of TB drug candidates presented brief updates on progress made in the clinical development of their candidates. Click the presentation name to...